Last reviewed · How we verify

dihydroartemisinin-piperaquine plus azithromycin

Liverpool School of Tropical Medicine · Phase 3 active Small molecule

dihydroartemisinin-piperaquine plus azithromycin is a Small molecule drug developed by Liverpool School of Tropical Medicine. It is currently in Phase 3 development. Also known as: Eurartesim plus Zithromax.

At a glance

Generic namedihydroartemisinin-piperaquine plus azithromycin
Also known asEurartesim plus Zithromax
SponsorLiverpool School of Tropical Medicine
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about dihydroartemisinin-piperaquine plus azithromycin

What is dihydroartemisinin-piperaquine plus azithromycin?

dihydroartemisinin-piperaquine plus azithromycin is a Small molecule drug developed by Liverpool School of Tropical Medicine.

Who makes dihydroartemisinin-piperaquine plus azithromycin?

dihydroartemisinin-piperaquine plus azithromycin is developed by Liverpool School of Tropical Medicine (see full Liverpool School of Tropical Medicine pipeline at /company/liverpool-school-of-tropical-medicine).

Is dihydroartemisinin-piperaquine plus azithromycin also known as anything else?

dihydroartemisinin-piperaquine plus azithromycin is also known as Eurartesim plus Zithromax.

What development phase is dihydroartemisinin-piperaquine plus azithromycin in?

dihydroartemisinin-piperaquine plus azithromycin is in Phase 3.

Related